中国合理用药探索2025，Vol.22Issue(2)：79-84,6.DOI:10.3969/j.issn.2096-3327.2025.02.014
异丙托溴铵联合人干扰素α2b治疗呼吸道合胞病毒感染性肺炎患儿的临床疗效及安全性
Clinical Efficacy and Safety of Ipratropium Bromide Combined with Recombinant Human Interferon α2b in the Treatment of Children with Respiratory Syncytial Virus Infectious Pneumonia
摘要
Abstract
Objective:To investigate the clinical efficacy and safety of ipratropium bromide combined with recombinant human interferon α2b in the treatment of children with respiratory syncytial virus(RSV)infectious pneumonia.Methods:A total of 100 children with RSV infectious pneumonia treated in a hospital from January 1 to July 31,2023 were selected and divided into the control group and observation group by random number table method,with 50 patients in each group.Both groups were given conventional treatment such as antipyretic,antitussive and expectorant therapies,maintaining airway patency,correcting electrolyte disturbance,etc.The control group was treated with recombinant human interferon α2b spray,and the observation group was treated with ipratropium bromide solution for inhalation in addition to the treatment given in the control group.Both groups were treated for 7 consecutive days.The clinical response,time of improvement in clinical symptoms,inflammatory factors[interleukin-18(IL-18),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],immune function(CD3+,CD4+,CD8+and CD4+/CD8+)and adverse reactions were compared between the two groups.Results:After treatment,the total response rate in the observation group(90.00%)was higher than that in the control group(74.00%,P<0.05).The disappearance time of fever,cough,pulmonary rales and dyspnea in the observation group was shorter than that in the control group(P<0.05).The serum levels of IL-18,IL-6 and TNF-α were decreased in both groups,and were lower in the observation group than those in the control group(P<0.05).CD3+,CD4+and CD4+/CD8+were increased in both groups,and were higher in the observation group than those in the control group(P<0.05).CD8+was decreased in both groups,and was lower in the observation group than that in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Ipratropium bromide combined with recombinant human interferon α2b exhibited satisfactory clinical efficacy in the treatment of children with RSV infectious pneumonia,which can effectively improve the level of inflammatory factors and immune function,relieve clinical symptoms,without additional risks of adverse reactions.关键词
异丙托溴铵/人干扰素α2b/呼吸道合胞病毒/感染性肺炎/疗效/安全性Key words
ipratropium bromide/recombinant human interferon α2b/respiratory syncytial virus/infectious pneumonia/efficacy/safety分类
医药卫生引用本文复制引用
冯晓靖,岳瑾,王芳..异丙托溴铵联合人干扰素α2b治疗呼吸道合胞病毒感染性肺炎患儿的临床疗效及安全性[J].中国合理用药探索,2025,22(2):79-84,6.基金项目
2021年度河南省医学科技攻关计划联合共建项目(LHGJ20210634) （LHGJ20210634）
